GALNT6

Across TCGA pan-cancer cohorts, GALNT6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GALNT6 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GALNT6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GALNT6 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where GALNT6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.997	0.668	<.001	31	view →
HNSC	DFS	Quartile	II,III,IV	0.919	0.561	.001	30	view →
LUAD	DFS	Median	All	0.646	0.832	.003	11	view →
LSCC	DFS	Quartile	All	0.835	0.955	.023	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GALNT6–PDAC (OS)

Open the PDAC breakdown →